The chronic myeloid leukemia (CML) mutation
View the animation to learn about the Philadelphia chromosome, the abnormal chromosome that causes chronic myeloid leukemia.
chronic myeloid leukemia,philadelphia chromosome,abnormal chromosome,cml,leukemia,mutation,animation
- ID: 15994
- Source: DNALC.DNAi
Related Content
15706. Philadelphia chromosome
A mutation that gives rise to the Philadelphia chromosome gives rise to leukemia.
1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevec⢠inhibits the molecular cause of chronic myeloid leukemia.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
1012. Diagnosis, Targeted therapies: Targeting activators
In this section learn that tyrosine kinases are a family of activator proteins that trigger the cell signaling process leading to cell growth and division.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
1014. Diagnosis, Targeted therapies: Targeting activators, Sawyer 2
Professor Charles Sawyer explains that Gleevec is a pill taken once a day and works remarkably well in all phases of CML.
1015. Diagnosis, Targeted therapies: Targeting activators, Sawyer 3
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
1016. Diagnosis, Targeted therapies: Targeting activators, Sawyer 4
Professor Charles Sawyer explains that EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.